Study Overview: This research is testing a new drug called DMX-200 (repagermanium) for those with a rare kidney disease called FSGS (Focal Segmental Glomerulosclerosis). FSGS is a condition where some parts of the kidney are scarred, making it hard for the kidneys to filter blood. DMX-200 is being tested alongside ARBs (Angiotensin Receptor Blockers), which are medicines that help relax blood vessels and reduce blood pressure. The study lasts for 104 weeks and aims to see if DMX-200 is safe and effective.
- Study Length: The entire study, including follow-ups, can take up to 230 weeks.
- Participation: Requires regular visits and medication intake; expect detailed health monitoring.
- Eligibility: Patients aged 12-80 with confirmed FSGS can join; some conditions may exclude participation.
Participants will receive either the actual drug or a placebo (a harmless pill with no medicine) without knowing which they get. The research also includes a follow-up period to check long-term effects and safety. If you're interested, ensure you meet the health and medication requirements and are ready for the commitment in time and visits.